How do you sequence deucravacitinib relative to JAK inhibitors when avoiding injections is a priority in a patient with active peripheral psoriatic arthritis?

This is a good question - guideline updates will likely address this in the future, as experience is gained since deucravacitinib was just approved for active PsA in March 2026. Both medication classes are oral, so the decision rests on payer/insurance considerations, safety, and prior therapies. He...